Effect of transcatheter aortic valve implantation (TAVI) in acquired von Willebrand syndrome and molecular analysis of high-molecular-weight multimers.

26 August 2017 (00:00 - 00:00)

Organised by:

About the speaker

Doctor Marco Alfonso Perrone

Tor Vergata University Hospital Polyclinic, Rome (Italy)

10 More presentations in this session

Presentation thumbnail

Combination of pre-existing atrial fibrillation and coronary artery disease associates with poor outcome in patients who undergo TAVI

Doctor H. Hioki (Tokyo, JP)

Abstract Slides

Presentation thumbnail

Transcatheter aortic valve replacement alters expression levels of circulating myocardial microRNAs

Doctor F. Jansen (Cologne, DE)

Abstract Slides

Presentation thumbnail

Cardiac biomarkers and clinical scores for risk stratification in patients with severe symptomatic aortic stenosis undergoing TAVI. Which ranks first now?

Mrs A. Stundl (Bonn, DE)

Abstract Slides

Presentation thumbnail

Peri-procedural myocardial injury depends on transcatheter heart valve type but does not predict mortality in patients after tavi

Mrs A. Stundl (Bonn, DE)

Abstract Slides

Presentation thumbnail

Impact of diastolic dysfunction severity on outcome of severe aortic stenosis patients undergoing transcatheter aortic valve replacement

Professor R. Waksman (Washington, DC, US)

Access the full session

Session thumbnail

Poster session 1 - Risk stratification and prognosis after TAVI

The Event

ESC Congress 2017

26 August - 30 August 2017

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources